Abstract
This chapter discusses the quality use of medicines in the management of mental health conditions in rural and remote settings. It addresses the clinical reasoning processes, frameworks and policies that support safe and effective use of medicines. Recognizing that many people are able to maintain or regain their health without using medicines and not all instances of mental distress require a pharmacological remedy. The chapter highlights the distinctive features of rural and remote practice necessary for the safe and appropriate use of medicines in the treatment of mental health conditions. These include decreased access to health services and reliable medicine supply chains, cultural diversity, communication challenges, physiological variations, and translation of medicinal trial data to clinical practice. The risks associated with medicine use can be minimized through a structured approach to the decision-making process, incorporating principles of quality use of medicines, good medicines management framework, best practice and standard treatment guidelines, and use of evidence based resources.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Andary L, Stolk Y, klimidis S, Klimdis S. Assessing mental health across cultures. Brisbane: Australian Academic Press; 2003.
Arora NK, McHorney CA. Patient preferences for medical decision making: who really wants to participate? Med Care. 2000;38(3):335–41.
Australian Bureau of Statistics. Health literacy, Australia, 2006. Australia, Canberra; 2008. Retrieved from https://www.abs.gov.au/ausstats/abs@.nsf/lookup/4102.0main+features20june+2009#endnote1
Australian Bureau of Statistics. Australian aboriginal and Torres Strait islander health survey: first results. Canberra: Australian Bureau of Statistics; 2013.
Australian Commission on Safety and Quality in Health Care. Health literacy: taking action to improve safety and quality; 2014. Retrieved from Sydney http://www.safetyandquality.gov.au/wp-content/uploads/2014/08/Health-Literacy-Taking-action-to-improve-safety-and-quality.pdf
Australian Government. Australian indigenous cultural heritage; 2016. Retrieved from http://www.australia.gov.au/about-australia/australian-story/austn-indigenous-cultural-heritage
Australian Health Ministers’ Advisory Council. National strategic framework for chronic conditions; 2017. Retrieved from Canberra http://www.health.gov.au/internet/main/publishing.nsf/content/A0F1B6D61796CF3DCA257E4D001AD4C4/$File/National%20Strategic%20Framework%20for%20Chronic%20Conditions.pdf
Australian Institute of Health and Welfare. Australia’s health 2020: in brief. Australia’s health series no. 17 Cat. no. AUS 232. Canberra: AIHW; 2020
Australian Institute of Health and Welfare. Mental health services in Australia; 2017. Retrieved from Canberra http://mhsa.aihw.gov.au/resources/workforce/
Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2020. Joint Formulary Committee. British National Formulary. London: Pharmaceutical Press. 2020.
Bean RB. Sir William Osler: aphorisms from his bedside teachings and writings. New York: Henry Schuman; 1950.
Joint Formulary Committee. British National Formulary. London: Pharmaceutical Press. 2020.
Burns J, Thomson N. Review of ear health and hearing among Indigenous Australians. Australian Indigenous HealthInfoNet. Perth, WA; 2013.
Cardiff L. ASPRINH project prescribing assessment toolkit; 2017. Retrieved from Canberra https://cdn3.scrvt.com/08ab3606b0b7a8ea53fd0b40b1c44f86/04e28a5e06baf490/d1e8a812ba02/ASPRINH-Toolkit.pdf
Commonwealth Department of Health and Ageing. The national strategy for quality use of medicines. Canberra; 2002.
Cutrer WB, Sullivan WM, Fleming AE. Educational strategies for improving clinical reasoning. Curr Probl Pediatr Adolesc Health Care. 2013;43(9):248–57. https://doi.org/10.1016/j.cppeds.2013.07.005.
de Vries T, Henning R, Hogerzeil H, Fresle D. Guide to good prescribing: a practical manual; 1994. Retrieved from Geneva http://apps.who.int/medicinedocs/pdf/whozip23e/whozip23e.pdf
Department of Health and Aging. The national strategy for quality use of medicines. Canberra: Commonwealth of Australia; 2002.
Diamond R. Drugs and the quality of life: the patient’s point of view. J Clin Psychiatry. 1985;46(5 Pt 2): 29–35.
Eades D. Communicative strategies in aboriginal English. In: Romaine S, editor. Language in Australia. Cambridge: Cambridge University Press; 1991. p. 84–93.
Easton K, Morgan T, Williamson M. Medication safety in the community: A review of the literature. National Prescribing Service. Sydney; 2009.
FDA. The drug development process; 2017. Retrieved from https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm
Griese EU, Ilett KF, Kitteringham NR, Eichelbaum M, Powell H, Spargo RM, …, Minchin RF. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics. 2001;11(1):69–76.
Hamrosi K, Taylor S, Aslani P. Issues with prescribed medications in aboriginal communities: aboriginal health workers’ perspectives. Rural Remote Health. 2006;6:2.
Health Workforce Data. The national health workforce dataset-pharmacy 2015; 2015. Retrieved from Canberra, ACT http://www.health.gov.au/internet/main/publishing.nsf/content/health_workforce_data
Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20(6):699–702.
Humphreys J, Wakerman J, Wells R, Kuipers P, Jones J, Entwistle P, Harvey P. Improving primary health care workforce retention in small rural and remote communities – how important is ongoing education & training? Australian Primary Care Research Institute, Australian National University. Canberra; 2007.
Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are underrepresented in clinical trials: a review of the literature. Health Soc Care Community. 2004;12(5):382–8. https://doi.org/10.1111/j.1365-2524.2004.00507.x.
Indigeneous Allied Health Australia. Position paper: Culturally responsive health care. Deakin West ACT; 2013.
Kaminsky BM, Bostwick JR, Guthrie SK. Alternate routes of administration of antidepressant and antipsychotic medications. Ann Pharmacother. 2015;49(7):808–17. https://doi.org/10.1177/1060028015583893.
Lambert T. Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Aust Prescr. 2011;34:97–9.
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167.
Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatr Serv. 2000;51(10):1254–8. https://doi.org/10.1176/appi.ps.51.10.1254.
Lum I, Mitchell C, Coombes I. The competent prescriber: 12 core competencies for safe prescribing. Aust Prescr. 2013;36:13–6.
Lurie SN. Psychological issues in treatment of the “chemical imbalance”. Am J Psychother. 1991;45(3):348–58.
Marmion D, Obata K, Troy J. Community, identity, wellbeing:the report of the second national indigenous languages survey; 2014. Retrieved from Canberra ACT https://aiatsis.gov.au/sites/default/files/products/report_research_outputs/2014-report-of-the-2nd-national-indigenous-languages-survey.pdf
National Aboriginal Community Controlled Health Organisation. Cultural safety; 2015. Retrieved from http://www.naccho.org.au/promote-health/cultural-safety/
NPS. Competencies required to prescribe medicines: putting quality use of medicines into practice; 2012. Retrieved from Sydney NSW http://www.nps.org.au/_data/assets/pdf_file/0004/149719/Prescribing_Competencies_Framework.pdf
Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, Forbes A. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev. 2014;(10):Mr000035. https://doi.org/10.1002/14651858.MR000035.pub2.
PhRMA. Biopharmaceutical research & development: the process behind new medicines; 2015. Retrieved from Washington, DC http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22(6):298–305.
Remote Primary Health Care Manuals. Medicines book for aboriginal and Torres Strait islander health practitioners. 4th ed. Alice Springs: Centre for Remote Health; 2017.
Ritter J, Rang H, Henderson G, Henderson G, Flower R. Rang & Dale’s pharmacology, vol. 8. Philadelphia: Elsevier Churchill Livingstone; 2016.
Robertson M. An overview of psychiatric ethics; 2012. Retrieved from Gladesvillee NSW http://www.heti.nsw.gov.au/Global/HETI-Resources/psvchiatry/An%20Overview%20of%20Psychiatric%20Ethics.pdf
Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723–33. https://doi.org/10.1176/appi.ajp.2012.12040474.
Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiat. 2014;71(12):1409–21. https://doi.org/10.1001/jamapsychiatry.2014.1319.
Office of the High Commissioner for Human Rights. Principles for the protection of persons with mental illness and the improvement of mental health care. Geneva, Switzerland; 1991. Retrieved from https://www.who.int/mental_health/policy/en/UN_Resolution_on_protection_of_persons_with_mental_illness.pdf
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–60. https://doi.org/10.1056/NEJMsa065779.
Usher K, Foster K, Bullock S. Psychopharmacology for health professionals. Chatswood: Elsevier; 2009.
World Health Organization. How to develop and implement a national drug policy. 2nd ed. Geneva: World Health Organization; 2002.
Zhou S-F, Liu J-P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295. https://doi.org/10.1080/03602530902843483.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Speare, T., Gilbert, A., Tabart, M., Tsai, D. (2021). Quality Use of Psychotropic Medicines in Rural and Remote Setting. In: Carey, T.A., Gullifer, J. (eds) Handbook of Rural, Remote, and very Remote Mental Health. Springer, Singapore. https://doi.org/10.1007/978-981-15-6631-8_26
Download citation
DOI: https://doi.org/10.1007/978-981-15-6631-8_26
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-6630-1
Online ISBN: 978-981-15-6631-8
eBook Packages: MedicineReference Module Medicine